3.4. Cellular Immunity Assessment
Parameters of cellular immunity were determined for the same 27 randomly picked participants from the Vaccine Group in Stage 3 of the phase II study in the 18–60 age cohort. Cellular immune response was assessed in the whole blood of the trial participants using QuantiFERON SARS-CoV-2 Starter Set (Qiagen, Germany) by stimulation of IFN-γ production by S-protein-specific CD4 and CD4/CD8 T cells using two SARS-CoV-2 S protein peptide pools (Ag1 and Ag2, respectively). The data are summarized in Compared to baseline levels, we observed a statistically significant (